Search alternatives:
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
mg decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
mg decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1441
Mean SARS-CoV-2 viral load log 10 between groups.
Published 2024“…The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”
-
1442
-
1443
Photo-affinity labelling and biochemical analyses identify the target of trypanocidal simplified natural product analogues
Published 2017“…We show that (i) <b>compound 1</b> decreases cellular ATP levels (ii) by inhibiting oxidative phosphorylation (iii) at the F<sub>o</sub>F<sub>1</sub>-ATP synthase. …”
-
1444
-
1445
Flibanserin’s neuroprotective effects are 5-HT<sub>1A</sub> receptor-mediated.
Published 2016“…A 6 mg/kg dose of flibanserin in 5-HT<sub>1A</sub> knockout mice (5-HT1A KO + 6 mg/kg Flibanserin, <i>red</i>) resulted in average receptor plus thickness that was not significantly different from vehicle-injected and naïve mice. …”
-
1446
-
1447
-
1448
Discovery of Oral AMP-Activated Protein Kinase Activators for Treating Hyperlipidemia
Published 2024Subjects: -
1449
-
1450
-
1451
-
1452
-
1453
Flowchart of patients.
Published 2024“…Mortality at 30 days was 3.6% and we found that the mortality decreases with increasing of the hospital activity. …”
-
1454
-
1455
-
1456
Initial treatment regimen.
Published 2024“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”
-
1457
Patients baseline characteristics.
Published 2024“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”
-
1458
Overall survival.
Published 2024“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”
-
1459
Progression-free survival by treatment.
Published 2024“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”
-
1460
Maintenance regimen and adverse event management.
Published 2024“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”